Following 5 years of work by INFACT, In April 2018 a new Mandatory Action for the use of Valproate in women of child bearing age was put in place by the Medicines & Healthcare Products Regulatory Agency (MHRA) called the Pregnancy Prevention Plan (PPP). This was to ensure the women were given the warnings of the risk of Valproate when used in pregnancy and those who could use other medications were able to do so. Any women who had tried all other possibilities continued to use Valproate with the use of the PPP. It is important to ensure all women are made aware of this and for INFACT to report any way in which this new system may be failing.
INFACT and its parental support group FACSA have been inundated with calls recently from women prescribed Valproate explaining the confusion and laxck of understanding this has caused.
In order for INFACT and FACSA to understand whether the PPP is to be sucessful it is important we can produce percentages to the MHRA on our next meeting with them.